Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.03, read 2026-10-28
Ethical passes the values gate
Price100.10 USD
Fair value115.00
Ethical score70.0/100
Our investment reviews on this name
2026-10-28Read Accumulation100.39-0.3% to today Markdown gives way to Accumulation while volume is distributing
2026-09-04Read Markdown100.87-0.8% to today ✓Markup gives way to Markdown with volume flow in agreement
2026-07-02Read Markup104.52-4.2% to today First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Lantheus Holdings, Inc. holds its Accumulation at $100.10. Consolidating, no directional conviction, held for 44 days.
As held on the ledger · 2026-10-28
Phase
Accumulation
Quantitative state
Consolidating, no directional conviction, held for 44 days
Price at the screen
$100.10
Valuation
24.31 trailing · 15.74 forward price to earnings
Values screen
PASS· score 70.0
Beta
-0.06
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
27.81%
Below 33%
Interest-bearing debt is just 27.8% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
1.90%
Below 33%
Cash held in interest-bearing accounts and securities is 1.9% of assets, under the one-third limit.
Pass
Receivables
32.22%
Below 49%
Money owed to the company is 32.2% of assets, under the 49% limit.
Pass
Revenue purity
1.52%
Below 5%
Only 1.5% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Lantheus Holdings, clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 28%, inside the ~33% line, and interest is about 2% of its income, under the ~5% line, so it passes.
Read as at 2026-10-28. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when LNTH's ethical verdict changes
Today LNTH passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Fair value range in USD, drawn from the 2026-10-28 screen. The gold marker is the market price at the same screen. A 14.9% margin of safety to the base estimate.
Third-party analyst targets: 8 covering, consensus Hold. The average target sits +5% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-28 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Ultrasound scans rely on these agents yet growth has flatlined
Every hospital that needs a clearer heart scan or cancer image leans on specialised agents like the ones Lantheus supplies. The business clears the ethical screen and posts an 18% profit margin with 23% ROE, yet revenue is advancing only 1% and the shares already sit near analyst targets. That combination leaves almost no margin for error despite the stated fair value sitting 16% higher.
Forward earnings sit on a reasonable 16.9 times multiple and twelve analysts still carry a strong buy label. The difficulty is that low single digit top line growth rarely justifies stretching for modest valuation gaps in a sector where new competitors or reimbursement changes arrive quickly.
The real risk sits in the narrow growth runway and the unknown competitive moat. When revenue barely moves, any slip in margins or loss of key hospital contracts quickly erodes the thin cushion that remains. Analysis, not advice.
The risks · The things to watch: as a drug manufacturers - specialty & generic name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
LNTH trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 26%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (13 analysts) rates it strong buy, with a mean price target of $105.
2026-10-21Markdown$100.39+0.2%Entry 8
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 0.2% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 11% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 26%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (13 analysts) rates it strong buy, with a mean price target of $105.
2026-10-14Markdown$100.15+0.5%Entry 7
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 0.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 48% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 26%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (13 analysts) rates it strong buy, with a mean price target of $105.
2026-10-02Markdown$99.65-1.2%Entry 6
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 1.2% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 48% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 26%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (13 analysts) rates it strong buy, with a mean price target of $105.
2026-09-04Markdown · changed$100.87+1.2%Entry 5
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 1.2% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 48% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 26%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (13 analysts) rates it strong buy, with a mean price target of $105.
2026-08-04Markup$99.64-4.7%Entry 4
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 4.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 48% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 26%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (13 analysts) rates it strong buy, with a mean price target of $105.
2026-07-18Markup$104.52+0.0%Entry 3
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 48% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 26%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (13 analysts) rates it strong buy, with a mean price target of $105.
2026-07-03Markup$104.52+0.0%Entry 2
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Markup$104.52Entry 1
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
